ArticleACS biomaterials science & engineering2022
Mesoporous Silica Nanoparticles Improve Oral Delivery of Antitubercular Bicyclic Nitroimidazoles.
Article in ACS biomaterials science & engineering, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed.
- Overcoming the oral delivery challenges of venetoclax: advancing a clinically improved Bcl-2 inhibitor.Drug delivery and translational research · 2026Review
- Piperazine-Functionalized Nanoparticles Enable Oral Insulin Delivery in Obese Mice.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Hydrogel-mediated tri-modal nanoplatform for localized colorectal cancer therapy via smart chemo-photothermal-radiotherapy.Journal of biological engineering · 2026Article
- Comprehensive Review of Mesoporous Carbon and Mesoporous Silica in Poorly Soluble Drug Delivery: Insights into Drug Loading, Dissolution, Stability, and Pharmacological Performance.International journal of nanomedicine · 2026Review
- Triple-synergy bactericidal action: a mannose-decorated bioinspired coating on silver-mesoporous silica for eradicating multidrug-resistantRSC advances · 2025Article
- Recent advancements in drug development for pulmonary tuberculosis.Archives of microbiology · 2025Review
- In vivo antimicrobial activity of engineered mesoporous silica nanoparticles targeting intracellular mycobacteria.Nature communications · 2025Article
- CLINICALLY RELEVANT METALLIC NANOPARTICLES IN TUBERCULOSIS DIAGNOSIS AND THERAPY.Advanced therapeutics · 2025Article
- Synergistic effect of polymers in stabilizing amorphous pretomanid through high drug loaded amorphous solid dispersion.Drug delivery and translational research · 2025Article
- Oral Toxicity Study of Silicon Dioxide Nanoparticles on Fertility and Early Embryonic Development in Mice.International journal of nanomedicine · 2025Article
- A Review of Current Developments in Functionalized Mesoporous Silica Nanoparticles: From Synthesis to Biosensing Applications.Biosensors · 2024Review
- Superior doxorubicin cellular delivery effect established by optically active mesoporous silica nanoparticles.Drug delivery and translational research · 2024Article
- Breaking barriers: The potential of nanosystems in antituberculosis therapy.Bioactive materials · 2024Review
- Potential Applications and Additive Manufacturing Technology-Based Considerations of Mesoporous Silica: A Review.AAPS PharmSciTech · 2023Review
- Surface functionalization affects the retention and bio-distribution of orally administered mesoporous silica nanoparticles in a colitis mouse model.Scientific reports · 2023Article
- Advanced drug delivery and therapeutic strategies for tuberculosis treatment.Journal of nanobiotechnology · 2023Review
- Conveyance of sofosbuvir through vesicular lipid nanocarriers as an effective strategy for management of viral meningitis.RSC advances · 2023Article
- Virus-like Silica Nanoparticles Improve Permeability of Macromolecules across the Blood-Brain Barrier In Vitro.Pharmaceutics · 2023Article
- Translation of ionic liquids to be enteric nanoparticles for facilitating oral absorption of cyclosporine A.Bioengineering & translational medicine · 2023Article
- Nanotechnology as a Promising Approach to Combat Multidrug Resistant Bacteria: A Comprehensive Review and Future Perspectives.Biomedicines · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Pretomanid and MCC7433, a novel nitroimidazopyrazinone analog, are promising antitubercular agents that belong to the bicyclic nitroimidazole family. Despite possessing high cell permeability, they suffer from poor aqueous solubility and require specialized formulations in order to be orally bioavailable. To address this limitation, we investigated the use of mesoporous silica nanoparticles (MCM-41) as drug carriers. MCM-41 nanoparticles were synthesized using a sol-gel method, and their surface was further modified with amine and phosphonate groups. A simple rotary evaporation method was used to incorporate the compounds of interest into the nanoparticles, leading to a high encapsulation efficiency of ≥86% with ∼10% loading (w/w). An overall significant improvement of solubility was also observed, and the pharmacological activity of pretomanid and MCC7433 was fully retained when tested in vitro against
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.